Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

EP: 1.NCCN Guidelines Recommend Capivasertib, Fulvestrant for Certain Patients With Breast Cancer

EP: 2.Breast Cancer Treatment: NCCN Guideline Updates and Optimism at ASCO 2024

Now Viewing

EP: 3.Sequencing CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Treatment

1. What are the current guideline-recommended systematic treatments for HR-positive/HER2-negative (HR+/HER2-) breast cancer?
2. What are some of the differences between the CDK 4/6 inhibitors used in the management of HR+/HER2-? What factors drive treatment decision-making between available options? 

Related Videos

Related Content

Advertisement

June 28th 2024

Infection Risk With BTK Inhibitors Low, New CLL Study Finds

Jared Kaltwasser

Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

June 28th 2024

Zeroing in on Sarcoma Subtypes to Optimize Treatment Outcomes

Maggie L. Shaw

The field of sarcoma study is getting more specific, with clinical investigations drilling down to more specific subtypes of soft tissue sarcoma for better targeted therapies.

May 9th 2024

Frameworks for Advancing Health Equity: Urban Health Outreach

Giuliana Grossi

In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.

June 28th 2024

Certain Melanoma Subtype May Be More Sensitive to NK, T Cells

AJMC Contributor

Of 7 subtypes identified 10,000 melanoma cells, C4 Melanoma COCO1A was the only to show indications of being more sensitive to natural killer (NK) and T cells.

June 28th 2024

Rilzabrutinib Improves Asthma Symptoms in the First 2 Weeks of Treatment, Study Finds

Cameron Santoro Pearl Steinzor

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, discusses efficacy outcomes in patients with asthma who received rilzabrutinib.

Related Content

Advertisement

June 28th 2024

Infection Risk With BTK Inhibitors Low, New CLL Study Finds

Jared Kaltwasser

Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

June 28th 2024

Zeroing in on Sarcoma Subtypes to Optimize Treatment Outcomes

Maggie L. Shaw

The field of sarcoma study is getting more specific, with clinical investigations drilling down to more specific subtypes of soft tissue sarcoma for better targeted therapies.

May 9th 2024

Frameworks for Advancing Health Equity: Urban Health Outreach

Giuliana Grossi

In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.

June 28th 2024

Certain Melanoma Subtype May Be More Sensitive to NK, T Cells

AJMC Contributor

Of 7 subtypes identified 10,000 melanoma cells, C4 Melanoma COCO1A was the only to show indications of being more sensitive to natural killer (NK) and T cells.

June 28th 2024

Rilzabrutinib Improves Asthma Symptoms in the First 2 Weeks of Treatment, Study Finds

Cameron Santoro Pearl Steinzor

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, discusses efficacy outcomes in patients with asthma who received rilzabrutinib.